Literature DB >> 30517707

Transient Receptor Potential Ion Channels Mediate Adherens Junctions Dysfunction in a Toluene Diisocyanate-Induced Murine Asthma Model.

Lihong Yao1, Shuyu Chen2, Haixiong Tang3, Peikai Huang4, Shushan Wei4, Zhenyu Liang1, Xin Chen5, Hongyu Yang6, Ailin Tao2, Rongchang Chen1, Qingling Zhang4.   

Abstract

Disruption of epithelial cell-cell junctions is essential for the initiation and perpetuation of airway inflammation in asthma. We've previously reported compromised epithelial barrier integrity in a toluene diisocyanate (TDI)-induced occupational asthma model. This study is aimed to explore the role of transient receptor potential vanilloid 4 (TRPV4) and transient receptor potential ankyrin 1 (TRPA1) in the dysfunction of adherens junctions in TDI-induced asthma. Mice were sensitized and challenged with TDI for a chemical-induced asthma model. Selective blockers of TRPV4 glycogen synthase kinase (GSK)2193874, 5 and 10 mg/kg) and TRPA1 (HC030031, 10 and 20 mg/kg) were intraperitoneally given to the mice. Immunohistochemistry revealed different expression pattern of TRPV4 and TRPA1 in lung. TDI exposure increased TRPV4 expression in the airway, which can be suppressed by GSK2193874, while treatment with neither TDI alone nor TDI together with HC030031 led to changes of TRPA1 expression in the lung. Blocking either TRPV4 or TRPA1 blunted TDI-induced airway hyperreactivity, airway neutrophilia and eosinophilia, as well as Th2 responses in a dose-dependent manner. At the same time, membrane levels of E-cadherin and β-catenin were significantly decreased after TDI inhalation, which were inhibited by GSK2193874 or HC030031. Moreover, GSK2193874 and HC030031 also suppressed serine phosphorylation of glycogen synthase kinase 3β, tyrosine phosphorylation of β-catenin, as well as activation and nuclear transport of β-catenin in mice sensitized and challenged with TDI. Our study suggested that both TRPV4 and TRPA1 contribute critically to E-cadherin and β-catenin dysfunction in TDI-induced asthma, proposing novel therapeutic targets for asthma.
© The Author(s) 2018. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  E-cadherin; TRPs; asthma; toluene diisocyanate; β-catenin

Mesh:

Substances:

Year:  2019        PMID: 30517707     DOI: 10.1093/toxsci/kfy285

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  5 in total

1.  Anti-VEGF treatment suppresses remodeling factors and restores epithelial barrier function through the E-cadherin/β-catenin signaling axis in experimental asthma models.

Authors:  Ahmet Türkeli; Özge Yilmaz; Meral Karaman; Esra Toprak Kanik; Fatih Firinci; Sevinç İnan; Hasan Yüksel
Journal:  Exp Ther Med       Date:  2021-04-29       Impact factor: 2.447

2.  MiR-223 plays a protecting role in neutrophilic asthmatic mice through the inhibition of NLRP3 inflammasome.

Authors:  Wenjuan Xu; Yimin Wang; Ying Ma; Jiong Yang
Journal:  Respir Res       Date:  2020-05-18

3.  Toll-like Receptor 4 Deficiency Aggravates Airway Hyperresponsiveness and Inflammation by Impairing Neutrophil Apoptosis in a Toluene Diisocyanate-Induced Murine Asthma Model.

Authors:  Shuyu Chen; Yao Deng; Qiaoling He; Yanbo Chen; Weimin Sun; Ying He; Zehong Zou; Zhenyu Liang; Rongchang Chen; Lihong Yao; Ailin Tao
Journal:  Allergy Asthma Immunol Res       Date:  2020-07       Impact factor: 5.764

4.  Transient Receptor Potential Cation Channel Subfamily V Member 4 Mediates Pyroptosis in Chronic Obstructive Pulmonary Disease.

Authors:  Yafei Rao; Xiaoyan Gai; Jing Xiong; Yanqing Le; Yongchang Sun
Journal:  Front Physiol       Date:  2021-12-24       Impact factor: 4.566

5.  Louki Zupa decoction attenuates the airway inflammation in acute asthma mice induced by ovalbumin through IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway.

Authors:  Xi Huang; Hang Yu; Cong Xie; Yao-Long Zhou; Meng-Meng Chen; Han-Lin Shi; Wei-Feng Tang; Jing-Cheng Dong; Qing-Li Luo
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.